



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Dry Eye Disease Agents
(Cequa, Eysuvis, Miebo, Cyclosporine 0.05%
Ophthalmic Emulsion vial, Tyrvaya, Vevye, Xiidra) Page: 1 of 3

Effective Date: 4/4/2025 Last Review Date: 03/14/2025

Applies to: New Jersey Maryland Florida Kids Pennsylvania Kid

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for dry eye disease agents under the patient's prescription drug benefit.

Description:

FDA-approved Indications

Cequa

Cequa ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Eysuvis

Eysuvis is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

Miebo

Miebo (perfluorohexyl octane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Restasis

Restasis (Cyclosporine 0.05% ophthalmic emulsion vial) is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Tyrvaya

Tyrvaya (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.

Vevye

Vevye is indicated for the treatment of the signs and symptoms of dry eye disease.

Xiidra

Xiidra (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Applicable Drug List:

Preferred Agent:

Cyclosporine 0.05% Ophthalmic Emulsion Vial

Non-Preferred Agents:

Cequa

Eysuvis

Miebo



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Dry Eye Disease Agents
(Cequa, Eysuvis, Miebo, Cyclosporine 0.05% Ophthalmic Emulsion vial, Tyrvaya, Vevye, Xiidra) Page: 2 of 3

Effective Date: 4/4/2025 Last Review Date: 03/14/2025

Applies to: New Jersey Maryland Florida Kids Pennsylvania Kid

Tyrvaya
Vevye
Xiidra

Policy/Guideline:

Initial Coverage Criteria

Dry Eye Disease

Authorization may be granted when the requested drug is being prescribed for the treatment of dry eye disease when the following criteria is met:

- The request is for Cequa, Miebo, Cyclosporine 0.05% Ophthalmic Emulsion vial, Tyrvaya, Vevye, or Xiidra.
- The patient has experienced an inadequate treatment response, intolerance to, or a contraindication that would prohibit a trial to an artificial tears' product
- Requests for Cequa, Miebo, Tyrvaya, Vevye, or Xiidra, the patient is unable to take cyclosporine 0.05% ophthalmic emulsion vial due to a trial and inadequate treatment response, or intolerance, or a contraindication.

Short Term Dry Eye Disease

Authorization may be granted when the requested drug is being prescribed for the treatment of dry eye disease when the following criteria is met:

- The request is for Eysuvis AND the following criteria is met:
 - The requested drug is being prescribed for short-term use (up to two weeks).
 - The patient has experienced an inadequate treatment response, intolerance to, or a contraindication that would prohibit a trial to an artificial tears' product.

Continuation of Therapy

Dry Eye Disease

Authorization may be granted when the requested drug is being prescribed for the treatment of dry eye disease when ALL of the following criteria are met:

- The request is for Cequa, Miebo, Cyclosporine 0.05% Ophthalmic Emulsion vial, Tyrvaya, Vevye, or Xiidra.
- The patient achieved or maintained improvement in their signs and symptoms of dry eye disease from baseline (e.g., ocular irritation, redness, mucous discharge, reduced visual function, ocular surface damage, reduced tear production).

Short Term Dry Eye Disease

All patients (including new patients) requesting authorization for continuation of therapy for Eysuvis must meet ALL requirements in the initial coverage criteria section.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Dry Eye Disease Agents
(Cequa, Eysuvis, Miebo, Cyclosporine 0.05% Ophthalmic Emulsion vial, Tyrvaya, Vevye, Xiidra) Page: 3 of 3

Effective Date: 4/4/2025 Last Review Date: 03/14/2025

Applies to: New Jersey Maryland Florida Kids Pennsylvania Kid

Approval Duration and Quantity Restrictions:

Approval Duration:

- Cequa, Miebo, Cyclosporine 0.05% Ophthalmic Emulsion vial, Tyrvaya, Vevye, Xiidra (Dry eye disease): 12 months
- Eysuvis (Short term dry eye disease): 3 months

Quantity Level Limit:

Drug	Limit
Cequa (cyclosporine ophthalmic soln)	60 vials / 30 days
Miebo (perfluorohexyl octane ophthalmic soln)	1 multi-dose bottle (3 mL) / 30 days
cyclosporine ophthalmic emulsn	60 vials / 30 days
Tyrvaya (varenicline nasal spray soln)	2 nasal spray bottles (8.4 mL) / 30 days
Vevye (cyclosporine ophthalmic soln)	1 multi-dose bottle (2 mL) / 30 days
Xiidra (lifitegrast ophthalmic soln)	60 containers (1 carton) / 30 days

For short-term acute use.

Drug	Limit
Eysuvis (loteprednol etabonate ophthalmic susp 0.25%)	2 bottles (16.6 mL) / 90 days

References:

1. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; July 2022.
2. Eysuvis [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; November 2023.
3. Miebo [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc.; January 2024.
4. Restasis [package insert]. Irvine, CA: Allergan, Inc; September 2024.
5. Restasis Multidose [package insert]. Irvine, CA: Allergan, Inc; September 2024.
6. Tyrvaya [package insert]. Princeton, NJ: Oyster Point Pharma, Inc.; September 2024.
7. Vevye [package insert]. Nashville, TN: Harrow Eye, LLC.; November 2023.
8. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2020.
9. Lexicomp Online, AHFS DI (Adult and Pediatric Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed October 16, 2024.
10. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 10/16/2024).
11. Akpek EK, Amescua G, Farid M, et al. Dry Eye Syndrome Preferred Practice Pattern. Ophthalmology. 2019;126(1):P286-P334.
12. Pharmacy Auditing and Dispensing Job Aid: Billing Other Dosage Forms. Centers for Medicare and Medicaid Services. December 2015.